Click to enlarge
Sarepta’s hearings. Or how to get a drug approved on emotional grounds. Source: Boston Globe.
In the world of biotech, amazing things sometimes happen. This article is about one such amazing thing: Sarepta’s (NASDAQ:SRPT) twin sister drug, company and stock.
The twin sister, of course, is AveXis (NASDAQ:AVXS). Consider the following:
Both had drugs tested on very small trials. Both drugs were set against similar diseases (Spinal Muscular Atrophy for AVXS, Duchenne Muscular Dystrophy for SRPT, both leading to muscular function loss on account of genetic defects). Both diseases had many possible levels of severity. Both diseases affected children and had high emotional appeal. Both trials didn’t have a proper blind and randomized control group. This, combined with the levels of severity, opened up a large window for recruiting less severe cases and then claiming their outperformance of historical norms (for the disease) as representing the drug working. And, indeed, both trials had the same principal investigator, Jerry Mendell.
Given all these coincidences, what is this article about? Well, it’s about another interesting consequence:
Top Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)
Advisors’ Opinion:
- [By Keith Speights]
The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) shares made a slight gain on Tuesday after it was announced that the U.S. Food and Drug Administration (FDA) approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. Specifically, the agency approved Prolia (denosumab), driven by positive late-stage results.
- [By ]
Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.
Top Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)
Advisors’ Opinion:
- [By Stephan Byrd]
ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
- [By Logan Wallace]
BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.
A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.
- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.
Top Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors’ Opinion:
- [By Keith Speights]
I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.
- [By Brian Orelli]
The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”
- [By Max Byerly]
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.
Top Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)
Advisors’ Opinion:
- [By ]
What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.
- [By George Budwell]
Biotech heavyweight Biogen (NASDAQ:BIIB) has now lost over 13% of its value so far this year. To be fair, this year hasn’t been kind to biotechs in general, thanks to President Trump’s aggressive trade policies with China.But Biogen’s value has been declining at a far faster rate than the industry as a whole due to stiffer competition in the all-important multiple sclerosis (MS) space.
- [By Logan Wallace]
Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, April 24th. The biotechnology company reported $6.05 earnings per share for the quarter, topping the consensus estimate of $5.93 by $0.12. The firm had revenue of $3.13 billion for the quarter, compared to analyst estimates of $3.15 billion. Biogen had a net margin of 23.54% and a return on equity of 37.64%. Biogen’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.20 earnings per share. research analysts anticipate that Biogen will post 23.94 earnings per share for the current year.
- [By Chris Lange]
Biogen Inc. (NASDAQ: BIIB) is expected to report its first-quarter results early on Tuesday. The consensus forecast calls for $5.92 in earnings per share (EPS) and revenue of $3.15 billion. Shares of Biogen ended last week at $263.02. The consensus analyst price target is all the way up at $371.97. The 52-week trading range is $244.28 to $370.57.
